As efforts move forward to modulate EZH2 for anti-tumor benefit with small molecule inhibitors (Kim and Roberts, 2016; Adema and Colla, 2022), there will need to be human-centric studies on the role of EZH2 in human TILs. This evidence concerns the gene EZH2 and neoplasm.